Literature DB >> 32118836

Metoclopramide-Induced Acute Dystonia: Data From a Pediatric Emergency Unit.

Coskun Yarar1, Ayten Yakut1, Kursat Bora Carman1, Sabiha Sahin2, Ozan Kocak3, Serhat Ozkan4, Cengiz Bal5.   

Abstract

OBJECTIVES: Metoclopramide is a commonly used medication in pediatric practice, and dystonia is a common adverse effect of it. The present study aims to evaluate the clinical characteristics of metoclopramide-induced acute dystonic reactions (MIADRs) in pediatric patients admitted to the pediatric emergency unit.
METHODS: Twenty-eight patients were admitted with MIADRs between June 2004 and April 2016; they were enrolled into the study retrospectively.
RESULTS: The study group was composed of 13 females and 15 males with the mean ± SD age of the females higher than that of the males, 12.3 ± 4.5 and 7.8 ± 4.3 years, respectively. Only 9 (32.1%) of the patients were diagnosed as MIADRs at the time of admission. Seventeen patients (60.7%) received over the recommended daily dose of metoclopramide. Dystonia was focal in most of the patients, with the most affected parts consisting of the neck, eyes, and orolingual regions. In 9 of the patients, the dystonia was episodic in nature. Pharmacological treatment was used for 18 patients. No patients died, and none suffered long-term injury related to MIADRs.
CONCLUSIONS: Metoclopramide administration may be associated with the occurrence of acute dystonic reaction. Metoclopramide-induced acute dystonic reactions may be misdiagnosed, so detailed medical history gathering and a high index of suspicion are warranted. Our data suggest that MIADRs may be dose related and that there may be age- and sex-related differences in the epidemiology of MIADRs.

Entities:  

Year:  2020        PMID: 32118836     DOI: 10.1097/PEC.0000000000001960

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  1 in total

1.  Clinical Consequences of Motor Behavior as Transdiagnostic Phenomenon.

Authors:  Peter N Van Harten; Lydia E Pieters
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.